The Pharmacokinetics and Safety of ABT-751, a Novel,Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study Anne Hagey, Jordan Berlin, et al. Clin Cancer Res 2006;12:2834-2840
Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study Jason A. Segreti,James S. Polakowski,et al. Cancer Chemother Pharmacol 2004;54: 273–281
http://aacrmeetingabstracts.org/cgi/content/abstract/2006/1/1021-c
ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature. Luo Y et al. Anticancer Drugs. 2009 Jul;20(6):483-92.
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.